Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2018’, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma)

- The report reviews pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutics and enlists all their major and minor projects

- The report assesses Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

Adgero Biopharmaceuticals Holdings Inc

Amgen Inc

Biofrontera AG

Biosceptre International Ltd

Bristol-Myers Squibb Co

Cannabis Science Inc

Galderma SA

Laboratories Ojer Pharma SL ...

4SC AG

Adgero Biopharmaceuticals Holdings Inc

Amgen Inc

Biofrontera AG

Biosceptre International Ltd

Bristol-Myers Squibb Co

Cannabis Science Inc

Galderma SA

Laboratories Ojer Pharma SL

LEO Pharma A/S

Loxo Oncology Inc

Mayne Pharma Group Ltd

MediGene AG

Medivir AB

Merck & Co Inc

PellePharm Inc

Regeneron Pharmaceuticals Inc

Replimune Ltd

Senhwa Biosciences Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Transgene SA

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview 6

Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Development ...

Table of Contents

Table of Contents 2

Introduction 5

Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview 6

Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Development 7

Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment 13

Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development 21

Basal Cell Carcinoma (Basal Cell Epithelioma) - Drug Profiles 32

Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects 203

Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products 205

Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones 206

Appendix 214

List of Tables

List of Tables

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2018

Number of Products under Development by Companies, H2 ...

List of Tables

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by 4SC AG, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Amgen Inc, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biofrontera AG, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biosceptre International Ltd, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Bristol-Myers Squibb Co, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Cannabis Science Inc, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Galderma SA, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Laboratories Ojer Pharma SL, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by LEO Pharma A/S, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Loxo Oncology Inc, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Mayne Pharma Group Ltd, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by MediGene AG, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Medivir AB, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Merck & Co Inc, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by PellePharm Inc, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Replimune Ltd, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Senhwa Biosciences Inc, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Transgene SA, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H2 2018 (Contd..1), H2 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2018

Number of Products under Development by Companies, H2 ...

List of Figures

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports